Popular Trials
PARP Inhibitor
Cediranib + Olaparib for Advanced Prostate Cancer
Recruiting1 awardPhase 2
La Jolla, California
This trial looks at how well olaparib, with or without cediranib, works to treat patients with metastatic prostate cancer. Olaparib is a PARP inhibitor, which means it prevents PARP proteins from repairing DNA mutations. This may stop tumor cells from growing. Cediranib is an enzyme inhibitor that may also stop tumor cell growth.
Monoclonal Antibodies
REGN4336 + Cemiplimab for Prostate Cancer
Recruiting1 awardPhase 1 & 2
Philadelphia, Pennsylvania
This trial is testing a new cancer drug called REGN4336, alone or with other drugs, to see if it is safe and effective. It aims to help the immune system attack cancer cells. The study focuses on finding the right dose and understanding side effects.
CAR T-cell Therapy
JNJ-78278343 for Prostate Cancer
Recruiting1 awardPhase 1
New York, New York
This trial tests a new medicine that helps immune cells find and kill advanced prostate cancer cells. It is for patients whose cancer has spread and does not respond to usual treatments. The medicine works by linking immune cells to cancer cells, prompting an immune attack on the cancer.
Popular Filters
Trials for Prostate Cancer Patients
Imaging Scans for Prostate Cancer
Recruiting3 awardsPhase 4
Los Angeles, California
This trial will study patients with advanced prostate cancer who are undergoing a specific type of therapy at a VA hospital in Los Angeles. The patients will have several imaging scans before and after the therapy to track the
Hormone Therapy
Relugolix + Abiraterone Acetate vs Leuprolide + Abiraterone Acetate for Prostate Cancer
Recruiting2 awardsPhase 3
Atlanta, Georgia
"This trial compares the effects of two different hormone therapies, leuprolide and abiraterone acetate, versus relugolix and abiraterone acetate on the heart in prostate
Chemotherapy
Opevesostat-Based Treatments for Prostate Cancer
Recruiting1 awardPhase 1 & 2
Montreal, Quebec
This trial is a part of a larger study focusing on experimental treatments for advanced prostate cancer. The specific goal of this substudy is to assess the safety and effectiveness of using opevesostat alone
Radioisotope Therapy
Cu-SAR-bisPSMA for Prostate Cancer
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is testing a new radioactive treatment called 67Cu-SAR-bisPSMA in patients with advanced prostate cancer that has spread and does not respond to hormone treatments. The treatment works by sticking to cancer cells and using radioactivity to destroy them.
Trials for Adenocarcinoma Patients
Imaging Scans for Prostate Cancer
Recruiting3 awardsPhase 4
Los Angeles, California
This trial will study patients with advanced prostate cancer who are undergoing a specific type of therapy at a VA hospital in Los Angeles. The patients will have several imaging scans before and after the therapy to track the
Hormone Therapy
Relugolix + Abiraterone Acetate vs Leuprolide + Abiraterone Acetate for Prostate Cancer
Recruiting2 awardsPhase 3
Atlanta, Georgia
"This trial compares the effects of two different hormone therapies, leuprolide and abiraterone acetate, versus relugolix and abiraterone acetate on the heart in prostate
Chemotherapy
Opevesostat-Based Treatments for Prostate Cancer
Recruiting1 awardPhase 1 & 2
Montreal, Quebec
This trial is a part of a larger study focusing on experimental treatments for advanced prostate cancer. The specific goal of this substudy is to assess the safety and effectiveness of using opevesostat alone
Radioisotope Therapy
Cu-SAR-bisPSMA for Prostate Cancer
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is testing a new radioactive treatment called 67Cu-SAR-bisPSMA in patients with advanced prostate cancer that has spread and does not respond to hormone treatments. The treatment works by sticking to cancer cells and using radioactivity to destroy them.
Trials for Metastatic Patients
Imaging Scans for Prostate Cancer
Recruiting3 awardsPhase 4
Los Angeles, California
This trial will study patients with advanced prostate cancer who are undergoing a specific type of therapy at a VA hospital in Los Angeles. The patients will have several imaging scans before and after the therapy to track the
Chemotherapy
Opevesostat-Based Treatments for Prostate Cancer
Recruiting1 awardPhase 1 & 2
Montreal, Quebec
This trial is a part of a larger study focusing on experimental treatments for advanced prostate cancer. The specific goal of this substudy is to assess the safety and effectiveness of using opevesostat alone
Radioisotope Therapy
Cu-SAR-bisPSMA for Prostate Cancer
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is testing a new radioactive treatment called 67Cu-SAR-bisPSMA in patients with advanced prostate cancer that has spread and does not respond to hormone treatments. The treatment works by sticking to cancer cells and using radioactivity to destroy them.
Trials With No Placebo
Imaging Scans for Prostate Cancer
Recruiting3 awardsPhase 4
Los Angeles, California
This trial will study patients with advanced prostate cancer who are undergoing a specific type of therapy at a VA hospital in Los Angeles. The patients will have several imaging scans before and after the therapy to track the
Hormone Therapy
Relugolix + Abiraterone Acetate vs Leuprolide + Abiraterone Acetate for Prostate Cancer
Recruiting2 awardsPhase 3
Atlanta, Georgia
"This trial compares the effects of two different hormone therapies, leuprolide and abiraterone acetate, versus relugolix and abiraterone acetate on the heart in prostate
Chemotherapy
Opevesostat-Based Treatments for Prostate Cancer
Recruiting1 awardPhase 1 & 2
Montreal, Quebec
This trial is a part of a larger study focusing on experimental treatments for advanced prostate cancer. The specific goal of this substudy is to assess the safety and effectiveness of using opevesostat alone
Radioisotope Therapy
Cu-SAR-bisPSMA for Prostate Cancer
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is testing a new radioactive treatment called 67Cu-SAR-bisPSMA in patients with advanced prostate cancer that has spread and does not respond to hormone treatments. The treatment works by sticking to cancer cells and using radioactivity to destroy them.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.